An eye toward the clinic, Israel’s Compugen works to transform itself admin June 8, 2017 Blog Read more: https://www.bioworld.com/report/BWT053017Compugen.pdf You Might Also Like NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting March 6, 2017 פריצת הדרך הישראלית שתמנע עיוורון בקשישים May 11, 2017 BrainStorm seeks early approval for stem cell treatment in Canada February 26, 2017
NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting March 6, 2017
